Nobelpharma has signed a license agreement for the use of ProBioGen’s AGE1.CR.pIX vaccine production platform to develop theirlead vaccine.
The signing of the agreement is yet another milestone in a series of fruitful collaborations between Nobelpharma and ProBioGen, among them the successful development of a highly efficient manufacturing process for Nobelpharma’s viral vaccine.
ProBioGen is a specialist in the development and manufacturing of complex therapeutic proteins. Combining both state-of-the-art protein and virus platforms, based on ProBioGen’s CHO.RiGHT and AGE1.CR expression and manufacturing platforms, respectively, together with intelligent product-specific technologies, yield biologics with optimized properties.
The advantages of ProBioGen’s cell-based production platform for industrial processes are evident. It is designed as true suspension cell line, the AGE1.CR.pIX grows in chemically defined medium and is free of any adventitious agents. This allows cultivation in large bioreactors with reduced lead times and thus a more controlled production process in closed systems.